Eupraxia Pharmaceuticals (NASDAQ:EPRX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01), Zacks reports.

Eupraxia Pharmaceuticals Trading Up 2.6%

EPRX traded up $0.19 during trading on Tuesday, reaching $7.61. 114,678 shares of the company were exchanged, compared to its average volume of 207,401. The stock has a market cap of $459.87 million, a P/E ratio of -7.39 and a beta of 1.19. The firm has a 50 day moving average of $7.35 and a 200 day moving average of $7.25. Eupraxia Pharmaceuticals has a 52 week low of $3.67 and a 52 week high of $9.32.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Guardian Wealth Advisors LLC NC bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at about $76,000. Aptus Capital Advisors LLC bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at about $76,000. Bank of America Corp DE boosted its stake in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in Eupraxia Pharmaceuticals during the third quarter valued at about $71,000. Finally, Geode Capital Management LLC bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at about $105,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on EPRX shares. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. William Blair began coverage on Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.